Key facts
- Topaz Biosciences’s last known valuation is $10.0M (Mar 2025).
- It has raised $1.4M across 1 recorded rounds; the latest was Seed Round ($1.4M) in Mar 2025.
- Topaz Biosciences has filed 1 Form D with the SEC, most recently Mar 2025 ($1.4M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Topaz Biosciences
Funding rounds
1 roundsAbout Topaz Biosciences
Developer of enzyme-based ingredients designed for rebalancing the skin microbiome. The company's platform utilizes natural biodiversity and synthetic biology to design enzymes that selectively reduce harmful bacteria while preserving beneficial ones, enabling researchers to address conditions such as eczema and acne through clinically proven formulations that restore skin health.
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2022
- Employees
- 3
- Website
- topaz.bio/
- Ownership
- Privately Held (backing)
Topaz Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Topaz Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Topaz Biosciences in its N-PORT filings yet. We sweep new filings monthly.